TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01709318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel (ENG)
Description: Daily release of 75, 100, 120 or 125 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel (ENG)
Description: Daily release of 75, 100, 120 or 125 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel (ENG)
Description: Daily release of 75, 100, 120 or 125 μg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etonogestrel (ENG)
Description: Daily release of 75, 100, 120 or 125 μg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethinyl estradiol (EE)
Description: Daily release of 15 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol (E2)
Description: Daily release of 300 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol (E2)
Description: Daily release of 300 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol (E2)
Description: Daily release of 300 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol (E2)
Description: Daily release of 300 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol (E2)
Description: Daily release of 300 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol (E2)
Description: Daily release of 300 μg
Study: NCT00320281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin A
Description: Injection of BTXA into cervical and upper back muscles based on treatment plan prescribed for each participant individually based on muscle soreness and tightness. Injections occured on one single clinic visit.Both the saline and BTXA were dosed in 25 cc syringes and looked the same for the physician performing the injections to ensure both participant and study physician remained blinded.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Injection of normal saline into cervical and upper back muscles was also based on treatment plan prescribed for each participant individually based on muscle soreness and tightness. Injections occured on one single clinic visit. Both the saline and BTXA were dosed in 25 cc syringes and looked the same for the physician performing the injections to ensure both participant and study physician remained blinded.
Study: NCT02755948

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV A Memphis 37
Description: Good Manufacturing Practices-certified RSV Memphis 37 10(4) PFU in 1 mL 25% sucrose/DMEM delivered by intranasal drops

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A/California/04/2009-likw (H1N1)
Description: Good Manufacturing Practices-certified Influenza A/California/04/09 3.5x10\^6 TCID50 in 1 mL in DPBS delivered by intranasal drops

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A/Belgium/4217/2015 (H3N2)
Description: Good Manufacturing Practices-certified Influenza A/Belgium/4217/2015 (H3N2) 3.5x10\^6 TCID50 in 1 mL in DPBS delivered by intranasal drops
Study: NCT00689273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04136309
Description: 125 mg capsules. Dose will be 4 capsules BID for 2 weeks for a total of 500 mg for each dosing interval.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be matched to PF-04136309. Dose, frequency, and duration same as PF-04136309.
Study: NCT01125917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
Study: NCT03841903

Intervention type: DIAGNOSTIC_TEST
Intervention: spinal cord MRI
Description: high-resolution spinal cord MRI sequences on a 3Tesla magnet (Siemens Prisma) with high contrast between SC and CSF as well as high contrast within the SC (grey-white matter contrast)

Intervention type: DIAGNOSTIC_TEST
Intervention: spinal cord MRI
Description: high-resolution spinal cord MRI sequences on a 3Tesla magnet (Siemens Prisma) with high contrast between SC and CSF as well as high contrast within the SC (grey-white matter contrast)

Intervention type: DIAGNOSTIC_TEST
Intervention: spinal cord MRI
Description: high-resolution spinal cord MRI sequences on a 3Tesla magnet (Siemens Prisma) with high contrast between SC and CSF as well as high contrast within the SC (grey-white matter contrast)

Intervention type: DIAGNOSTIC_TEST
Intervention: spinal cord MRI
Description: high-resolution spinal cord MRI sequences on a 3Tesla magnet (Siemens Prisma) with high contrast between SC and CSF as well as high contrast within the SC (grey-white matter contrast)
Study: NCT03574194

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Methionine-restricted diet
Description: The methionine-restricted diet diet (MRD) will begin 2 weeks prior to radiation therapy to deplete methionine stores in the body, continue during radiation, and extend for approximately 2 weeks after the last radiation fraction for a total of 6-10 weeks (depending on duration of radiation course).
Study: NCT01922973

Intervention type: OTHER
Intervention: Fasting
Description: normal volunteers fast from food on one occasion for 62.5 h; on another occasion fed 3 meals
Study: NCT04064931

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of niacin and other vitamins in plasma
Description: Detection of niacin and other vitamins in plasma

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of niacin and other vitamins in plasma
Description: Detection of niacin and other vitamins in plasma

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of niacin and other vitamins in plasma
Description: Detection of niacin and other vitamins in plasma
Study: NCT02107768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Other: Aerobic exercise The intervention group will conduct a 12 week training period with two training sessions of 60 minutes per week at a local hospital. The start shall be made within 6 weeks after stroke . The training shall be conducted in a group with a maximum of 10 participants and start running as new participants in the intervention group will be added.The intensity during the exercise program should be individualized and based on the initial tests . Patients should be advised to reach a degree of exertion 13-15/20,Rate of Perceived Exertion (Borg 's RPE scale) .~Two fitness goals was to be achieved during the training session~1. An individual training level corresponded to 50% or more of maximal oxygen uptake for at least 40 min ( Borg 9-11/20 ) . Which corresponds to 70 % of maximum heart rate.~2:nd 80% or more of the estimated maximum oxygen uptake during two periods of 8 minutes( Borg 13-15/20 ) . Which corresponds to 85 % of maximum heart rate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Other: Aerobic exercise The intervention group will conduct a 12 week training period with two training sessions of 60 minutes per week at a local hospital. The start shall be made within 6 weeks after stroke . The training shall be conducted in a group with a maximum of 10 participants and start running as new participants in the intervention group will be added.The intensity during the exercise program should be individualized and based on the initial tests . Patients should be advised to reach a degree of exertion 13-15/20,Rate of Perceived Exertion (Borg 's RPE scale) .~Two fitness goals was to be achieved during the training session~1. An individual training level corresponded to 50% or more of maximal oxygen uptake for at least 40 min ( Borg 9-11/20 ) . Which corresponds to 70 % of maximum heart rate.~2:nd 80% or more of the estimated maximum oxygen uptake during two periods of 8 minutes( Borg 13-15/20 ) . Which corresponds to 85 % of maximum heart rate.
Study: NCT04583384

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 1H-Spectroscopy MRI
Description: PRESS asymetric monovoxel  PROBE , TE 144 ms, TR 2500 ms, 768 or 1024 averages
Study: NCT03979339

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Description: A total volume of 32 ml of blood will be collected in each subject and separated in 4 10-mL EDTA vacutainer tubes EDTA tubes of 8 mL each.
Study: NCT03101215

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: phosphorus
Description: adding of phosphorus to high carbohydrate meal

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: phosphorus
Description: adding of phosphorus to high carbohydrate meal
Study: NCT04306224

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-002
Description: IMC-002 blocks the interaction between CD47 and SIRPα.
Study: NCT05297994

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu-M [Inactivated split influenza vaccine]
Description: solution for intramuscular injection, 0.5 ml

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated influenza split vaccine
Description: solution for intramuscular injection, 0.5 ml
Study: NCT01253616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vagus nerve stimulation (VNS)
Description: Daily stimulation synchronized with tones at the study assigned dose (amplitude, frequency, on/off cycle and treatment period).
Study: NCT01156324

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Online Stress Management Group (Upliv)
Description: Personalized online stress management program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Control group receiving routine care along with $50 gift certificate at end of cycle
Study: NCT04747938

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Energy accumulator
Description: All subjects treated with thermal therapy using the Energy Accumulator by acupoint concepts. The course included 8 sessions of treatment, twice every week for 4 weeks. Each session lasted for 30-45 minutes. During heat therapy, the ceramic nozzle of the Energy Accumulator was lightly pressed in contact of the skin, without any contact medium, and moved slowly along the meridians with some circular movements.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home exercise program
Description: Home exercises aimed at providing gentle mobilization at the shoulder and were capable of carrying out at home. Patients were requested to perform the movements on a daily basis within the first 4 weeks of treatment. Four movements were involved: Movement 1 - Pendular Exercise, Movement 2 - Circle Exercise, Movement 3 - Wall Climbing Exercise, and Movement 4 - Lie on bed and move both arms up and down.
Study: NCT01003431

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine, Live, Oral, Pentavalent
Description: \[Intervention name: RotaTeq™ administered concomitantly with Tritanrix™ HepB (DTwP)\] Three 2.0 mL oral doses of RotaTeq™ and three 0.5 mL intramuscular injections of Tritanrix™ HepB will be given at the same time with about 1 month between each administration.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP)
Description: Two 1.0 mL oral doses of Rotarix™ and three 0.5 mL intramuscular injections of Tritanrix™ HepB will be given at the same time with about 1 month between each administration (the second administration will be Tritanrix™ HepB only).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP)
Description: Three 2.0 mL oral doses of RotaTeq™ and three 0.5 mL intramuscular injections of INFANRIX™ will be given at the same time with about 1 month between each administration.
Study: NCT02120339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Study: NCT03269279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Medication used in conjunction with misoprostol for abortion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Medication used in conjunction with mifepristone for abortion
Study: NCT02305940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: An oral dose of 100 mg of Doxycycline once daily, for a total duration of 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An oral dose of one capsule of placebo once daily, for a total duration of 52 weeks
Study: NCT02690246

Intervention type: OTHER
Intervention: questionnaire
Description: a questionnaire based study
Study: NCT04521010

Intervention type: OTHER
Intervention: COVID-19 pandemic
Description: The aim of the study was to evaluate the staff absenteeism in the initial period of the COVID-19 pandemic at Wiktor Dega Orthopedic and Rehabilitation Clinical Hospital in Poznań Poznań as well as to assess the level of performance of medical services that were assigned to the Hospital under contract with National Health Fund, the payer of public health services in Poland.

Intervention type: OTHER
Intervention: COVID-19 pandemic
Description: The aim of the study was to evaluate the staff absenteeism in the initial period of the COVID-19 pandemic at Wiktor Dega Orthopedic and Rehabilitation Clinical Hospital in Poznań Poznań as well as to assess the level of performance of medical services that were assigned to the Hospital under contract with National Health Fund, the payer of public health services in Poland.
Study: NCT00646958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radezolid
Description: 450mg PO QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radezolid
Description: 450mg PO BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: 600mg PO BID
Study: NCT05134376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: During Episiotomy Repair, Women Will Be Watching Virtual Reality Glasses Accompanied by Music
Description: Unlike the experimental group, only video and music application will not be applied to the pregnant women included in the control group. Other applications will be done exactly.
Study: NCT03750396

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: Surgical resection for their metastatic lesions will be performed. Achievement of tumor-free margin is not mandatory.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: Deliver appropriate metastasis directed radiotherapy while minimizing exposure of surrounding normal tissues. Total radiation dose and fractions are various according to metastatic lesions (57\~97.5Gy/6\~10 Fraction).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: RFA is a localized thermal treatment technique designed to induce tumor destruction by heating the tumor tissue to temperatures that exceed 60℃. The alternating current of radiofrequency waves passing down from an uninsulated electrode tip into the surrounding tissues generates changes in the direction of ions and creates ionic agitation and frictional heating. This tissue heating then drives extracellular and intracellular water out of the tissue, resulting in tissue destruction by coagulative necrosis.
Study: NCT00228878

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Effects of Pulsatile IV insulin on Diabetic Quality of Life
Description: Patients receive weekly treatments of Pulsatile Intravenous insulin therapy. The patient's Endocrinologist determines the insulin dosage each week based upon the patient's response to treatment and their insulin resistance.
Study: NCT02915718

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: protein A immunoadsorption
Description: protein-A immunoadsorption for 5 days and i.v. IgG（0.5g/kg Body weight）substitution
Study: NCT05078632

Intervention type: OTHER
Intervention: Montreal-Toulouse Test adapted in eye tracking
Description: participant pass an eye tracking test to evaluate comprehension

Intervention type: OTHER
Intervention: Montreal-Toulouse Test adapted in eye tracking
Description: participant pass an eye tracking test to evaluate comprehension
Study: NCT03830333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane/Tazobactam
Description: Ceftolozane 1000 mg / tazobactam 500 mg by IV infusion every 8 hours for 4 to 14 days. Participants with CrCL of 30 to ≤ 50 mL/min will receive ceftolozane 500 mg / tazobactam 250 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole 500 mg by IV infusion every 8 hours for 4 to 14 days.
Study: NCT01429896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food challenge
Description: Double blind placebo controlled peanut challenge. Each challenge given with or without extrinsic factors exercise or sleep restriction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food challenge
Description: Double blind placebo controlled peanut challenge. Each challenge given with or without extrinsic factors exercise or sleep restriction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food challenge
Description: Double blind placebo controlled peanut challenge. Each challenge given with or without extrinsic factors exercise or sleep restriction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food challenge
Description: Double blind placebo controlled peanut challenge. Each challenge given with or without extrinsic factors exercise or sleep restriction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food challenge
Description: Double blind placebo controlled peanut challenge. Each challenge given with or without extrinsic factors exercise or sleep restriction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food challenge
Description: Double blind placebo controlled peanut challenge. Each challenge given with or without extrinsic factors exercise or sleep restriction.
Study: NCT01624545

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cranial CT scan
Description: Patients in this study arm will receive a cranial CT scan on day 2 and day 30 after evacuation of a chronic subdural hematoma in addition to neurological evaluation on day 2 and 30.
Study: NCT02912884

Intervention type: DRUG
Intervention: No cytoreductive vs cytoreductive drugs
Description: No cytoreductive treatment vs cytoreductive drugs (hydroxycarbamide, alpha-interferon, ruxolitinib).

Intervention type: DRUG
Intervention: No cytoreductive vs cytoreductive drugs
Description: No cytoreductive treatment vs cytoreductive drugs (hydroxycarbamide, alpha-interferon, ruxolitinib).
Study: NCT04384731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: poractant alfa
Description: Patient receiving surfactant (3 mL/kg of a poractant alpha solution diluted to 16 mg/mL, resulting in a total dose of 48mg/kg) administred by bronchial fibroscopy. The total volume will be divided in each of the five lobar bronchi.
Study: NCT01123018

Intervention type: BEHAVIORAL
Intervention: Memtrax Memory screening test
Description: Memory Screening test
Study: NCT03713567

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Experimentally induced plaque
Description: Experimentally induced plaque by suspension of oral hygiene only in the tested areas (tooth / implant), protected by a personalized stent made of plastic, according to the experimental gingivitis and mucositis model of 21 days of duration

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimentally induced plaque
Description: Experimentally induced plaque by suspension of oral hygiene only in the tested areas (tooth / implant), protected by a personalized stent made of plastic, according to the experimental gingivitis and mucositis model of 21 days of duration
Study: NCT04413318

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic device (VBM©)
Description: Continuous control of tracheal cuff pressure using an electronic device (VBM©) for 6-hours followed by continuous control using a pneumatic device (Nosten©) for 6-hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pneumatic device (Nosten©)
Description: Continuous control using a pneumatic device (Nosten©) for 6-hours followed by 6-hours of continuous control using an electronic device (VBM©).
Study: NCT02866578

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open lung protective ventilation strategy
Study: NCT00672880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-System Therapy
Description: 12 sessions of structured Self-System Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: 12 sessions of spine and muscle education including life style changes and medical treatments.
Study: NCT01461967

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single ascending doses
Study: NCT04592731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gel containing Acetylated Natural Nucleotides
Description: The study drug is a gel containing acetylated natural nucleotides.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: The vehicle gel contains no acetylated natural nucleotides but with the same base as study drug.
Study: NCT01064830

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical cyclosporine ophthalmic suspension 0.05%
Description: apply 2 drops to 2 target fingernails under occlusion daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle
Description: apply 2 drops to 2 target fingernails under occlusion daily for 20 weeks
Study: NCT00792818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcuma domestica extracts
Description: 1,500 mg per day (oral)divided into 3 times for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 1,200 mg/days (oral) divided into 3 times for 28 days
Study: NCT02606370

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unstable shoe
Description: Wearing Unstable shoes during 1 month